Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 9;6(2):30.
doi: 10.3390/biology6020030.

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin

Tatsuo Kanda  1 , Masato Nakamura  2 , Shin Yasui  3 , Yuki Haga  4 , Akinobu Tawada  5 , Eiichiro Suzuki  6 , Yoshihiko Ooka  7 , Koji Takahashi  8 , Reina Sasaki  9 , Shuang Wu  10 , Shingo Nakamoto  11 , Makoto Arai  12 , Fumio Imazeki  13 , Osamu Yokosuka  14
Affiliations

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin

Tatsuo Kanda et al. Biology (Basel). .

Abstract

The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated for 12 weeks with 400 mg of sofosbuvir plus weight-based ribavirin daily. This treatment led to higher sustained virologic response at 12-weeks post-treatment (SVR12) rates in both treatment-naïve and treatment-experienced patients. The efficacy of this treatment in compensated cirrhotics was the same as that in patients with chronic hepatitis. HCV GT-2a infection and lower estimated glomerular filtration rates (eGFR) tended to be associated with SVR12. Of 114 patients, 113 completed the combination of sofosbuvir plus ribavirin for 12 weeks. Seven patients without SVR12 did not have HCV NS5B-S282 mutations. The overall SVR12 rate was 90.4% (103 of 114). More effective therapeutic options with less adverse events are desired to achieve higher SVR rates in HCV GT-2 Japanese patients.

Keywords: genotype 2; hepatitis C virus; ribavirin; sofosbuvir; treatment-experienced.

PubMed Disclaimer

Conflict of interest statement

Tatsuo Kanda received research grants from Merck Sharp and Dohme (MSD), Chugai Pharm and AbbVie. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. The other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Study profile. Of 114 patients, 113 completed the combination of sofosbuvir plus ribavirin, and only one patient discontinued treatment. RVR, rapid virologic response; EOTR, end of treatment response.
Figure 2
Figure 2
Sustained virologic response at 12 weeks (SVR 12) rates for the various groups with or without cirrhosis. (a) Previous interferon treatment; (b) Age; (c) Gender; (d) HCV genotype (GT); and (e) HCV RNA viral load. LIU/mL, log IU/mL.
Figure 2
Figure 2
Sustained virologic response at 12 weeks (SVR 12) rates for the various groups with or without cirrhosis. (a) Previous interferon treatment; (b) Age; (c) Gender; (d) HCV genotype (GT); and (e) HCV RNA viral load. LIU/mL, log IU/mL.
See this image and copyright information in PMC

References

    1. Di Bisceglie A.M. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26:34S–38S. doi: 10.1002/hep.510260706. - DOI - PubMed
    1. Saito I., Miyamura T., Ohbayashi A., Harada H., Katayama T., Kikuchi S., Watanabe Y., Koi S., Onji M., Ohta Y., et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA. 1990;87:6547–6549. doi: 10.1073/pnas.87.17.6547. - DOI - PMC - PubMed
    1. Morgan T.R., Ghany M.G., Kim H.Y., Snow K.K., Shiffman M.L., De Santo J.L., Lee W.M., Di Bisceglie A.M., Bonkovsky H.L., Dienstag J.L., et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833–844. doi: 10.1002/hep.23744. - DOI - PMC - PubMed
    1. Kanda T., Imazeki F., Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol. Int. 2010;4:548–561. doi: 10.1007/s12072-010-9193-3. - DOI - PMC - PubMed
    1. Kanda T. Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. Hepatol. Int. 2017;11:38–44. doi: 10.1007/s12072-016-9749-y. - DOI - PubMed

LinkOut - more resources